Leerink Partnrs Comments on Axsome Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at Leerink Partnrs reduced their FY2026 earnings per share estimates for shares of Axsome Therapeutics in a report released on Monday, May 6th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of $1.60 per share for the year, down from their previous forecast of $1.85. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($3.75) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2027 earnings at $7.95 EPS and FY2028 earnings at $11.40 EPS.

A number of other analysts have also weighed in on the stock. Truist Financial restated a “buy” rating and set a $150.00 target price on shares of Axsome Therapeutics in a research note on Tuesday, March 26th. Robert W. Baird upped their price objective on Axsome Therapeutics from $108.00 to $112.00 and gave the stock an “outperform” rating in a research report on Tuesday. UBS Group assumed coverage on shares of Axsome Therapeutics in a report on Tuesday, February 6th. They set a “buy” rating and a $111.00 price objective on the stock. Citigroup dropped their price target on Axsome Therapeutics from $127.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Royal Bank of Canada lifted their price objective on Axsome Therapeutics from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $121.92.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $75.68 on Wednesday. Axsome Therapeutics has a 52 week low of $55.02 and a 52 week high of $98.40. The company has a fifty day simple moving average of $73.99 and a two-hundred day simple moving average of $75.73. The company has a quick ratio of 3.52, a current ratio of 3.63 and a debt-to-equity ratio of 0.93. The company has a market cap of $3.59 billion, a price-to-earnings ratio of -14.55 and a beta of 1.13.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.21) by $0.48. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%. The firm had revenue of $71.53 million for the quarter, compared to the consensus estimate of $70.38 million.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors have recently added to or reduced their stakes in AXSM. RTW Investments LP boosted its holdings in Axsome Therapeutics by 4.8% in the third quarter. RTW Investments LP now owns 4,489,596 shares of the company’s stock valued at $313,778,000 after purchasing an additional 205,319 shares during the last quarter. Perceptive Advisors LLC increased its stake in shares of Axsome Therapeutics by 115.5% in the fourth quarter. Perceptive Advisors LLC now owns 1,038,019 shares of the company’s stock worth $82,616,000 after buying an additional 556,370 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in Axsome Therapeutics by 57.4% in the fourth quarter. Point72 Asset Management L.P. now owns 837,201 shares of the company’s stock valued at $66,633,000 after acquiring an additional 305,264 shares in the last quarter. Bellevue Group AG boosted its stake in Axsome Therapeutics by 0.6% during the 4th quarter. Bellevue Group AG now owns 635,372 shares of the company’s stock valued at $50,569,000 after acquiring an additional 3,885 shares during the last quarter. Finally, Avidity Partners Management LP increased its position in shares of Axsome Therapeutics by 54.8% in the 4th quarter. Avidity Partners Management LP now owns 459,400 shares of the company’s stock worth $36,564,000 after purchasing an additional 162,600 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Buying and Selling at Axsome Therapeutics

In related news, Director Roger Jeffs sold 29,976 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $69.70, for a total value of $2,089,327.20. Following the transaction, the director now directly owns 120,756 shares of the company’s stock, valued at approximately $8,416,693.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Roger Jeffs sold 29,976 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $69.70, for a total value of $2,089,327.20. Following the completion of the sale, the director now directly owns 120,756 shares in the company, valued at approximately $8,416,693.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $77.24, for a total value of $1,904,892.88. The disclosure for this sale can be found here. 24.50% of the stock is owned by company insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.